304 related articles for article (PubMed ID: 36376839)
1. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
Liu Y; Gao Y; Wang Y; Zhao C; Zhang Z; Li B; Zhang T
BMC Cancer; 2022 Nov; 22(1):1175. PubMed ID: 36376839
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
Ricciuti B; Brambilla M; Cortellini A; De Giglio A; Ficorella C; Sidoni A; Bellezza G; Crinò L; Ludovini V; Baglivo S; Metro G; Chiari R
Clin Transl Oncol; 2020 May; 22(5):708-716. PubMed ID: 31332704
[TBL] [Abstract][Full Text] [Related]
3. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR
Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727
[TBL] [Abstract][Full Text] [Related]
5. Does Molecular Profiling of
Karim NA; Ullah A; Pathrose P; Fathallah H; Perry A; Morris JC; Wang J; Starnes SL
Curr Oncol; 2022 Jul; 29(7):4779-4790. PubMed ID: 35877239
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study.
Ma K; Guo Q; Li X
BMC Pulm Med; 2023 May; 23(1):175. PubMed ID: 37208639
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
Mellema WW; Masen-Poos L; Smit EF; Hendriks LE; Aerts JG; Termeer A; Goosens MJ; Smit HJ; van den Heuvel MM; van der Wekken AJ; Herder GJ; Krouwels FH; Stigt JA; van den Borne BE; Haitjema TJ; Staal-Van den Brekel AJ; van Heemst RC; Pouw E; Dingemans AM
Lung Cancer; 2015 Nov; 90(2):249-54. PubMed ID: 26415993
[TBL] [Abstract][Full Text] [Related]
9. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
10. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.
Landre T; Justeau G; Assié JB; Chouahnia K; Davoine C; Taleb C; Chouaïd C; Duchemann B
Cancer Immunol Immunother; 2022 Mar; 71(3):719-726. PubMed ID: 34378081
[TBL] [Abstract][Full Text] [Related]
11. KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.
Park S; Kim JY; Lee SH; Suh B; Keam B; Kim TM; Kim DW; Heo DS
Korean J Intern Med; 2017 May; 32(3):514-522. PubMed ID: 28407465
[TBL] [Abstract][Full Text] [Related]
12. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS
Ricciuti B; Alessi JV; Elkrief A; Wang X; Cortellini A; Li YY; Vaz VR; Gupta H; Pecci F; Barrichello A; Lamberti G; Nguyen T; Lindsay J; Sharma B; Felt K; Rodig SJ; Nishino M; Sholl LM; Barbie DA; Negrao MV; Zhang J; Cherniack AD; Heymach JV; Meyerson M; Ambrogio C; Jänne PA; Arbour KC; Pinato DJ; Skoulidis F; Schoenfeld AJ; Awad MM; Luo J
Ann Oncol; 2022 Oct; 33(10):1029-1040. PubMed ID: 35872166
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
[TBL] [Abstract][Full Text] [Related]
14. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy or antiangiogenic therapy plus chemotherapy as first-line treatment of patients with PD-L1(-) advanced non-squamous non-small cell lung cancer in a Chinese cohort.
Xia R; Li Y; Yang L; Huang M
Cancer Med; 2023 Jul; 12(13):14282-14292. PubMed ID: 37212483
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Lu Z; Ye M; Sun T; Wu S; Lin Z; Zhang X; Rao D; Zhang D; Ke Y; Chen Z
Ann Palliat Med; 2022 Jun; 11(6):2100-2109. PubMed ID: 35817745
[TBL] [Abstract][Full Text] [Related]
17. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
[No Abstract] [Full Text] [Related]
18. Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non-squamous non-small cell lung cancer patients.
Liu F; Wang F; He J; Zhou S; Luo M
Cancer Med; 2023 Jun; 12(12):13123-13134. PubMed ID: 37140194
[TBL] [Abstract][Full Text] [Related]
19. Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
Justeau G; Huchot E; Simonneau Y; Roa M; Le Treut J; Le Garff G; Bylicki O; Schott R; Bravard AS; Tiercin M; Lamy R; De Chabot G; Marty A; Moreau D; Locher C; Bernier C; Chouaid C; Descourt R
Lung Cancer; 2022 Dec; 174():45-49. PubMed ID: 36323057
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]